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Introduction
Chemical warfare nerve agents (CWNAs), such as sarin, irreversibly bind to acetylcholinesterase and induce a "cholinergic crisis" that causes numerous physiological events including miosis, salivation, respiratory failure, tremors, seizures, and death. Treatment regimens that typically include an anticholinergic (atropine), oxime (2-PAM chloride), and anticonvulsant (diazepam) reduce symptoms and lethality when administered before or quickly after an exposure (Lee, 2003) . Limited efficacy and a short therapeutic window of these treatments, however, require the development of new, more effective medical countermeasures. Numerous animal models are currently used to identify novel countermeasures (for review, see Pereira et al., 2014) . However, these are largely limited to male animals, and relatively little is known regarding the toxic effects of CWNAs and the therapeutic efficacy of countermeasures in females. Furthermore, developing medical countermeasures exclusively in males may result in a product that is not as safe for use in females. There is precedence for this safety concern because past FDA-approved pharmaceuticals have been withdrawn because of unintended adverse effects in women (Heinrich et al., 2001) . These facts underscore the need to include female subjects in scientific research, and to incentivize this inclusion, the National Institutes of Health plans to mandate the use of female subjects for preclinical trials (Clayton and Collins, 2014) . Thus, understanding how biological differences between males and females can affect outcomes is necessary for developing safe and effective medical countermeasures for CWNA exposure.
The relative sensitivity to the lethal effects of CWNAs between male and female rats is consistent in some reports but not others, and depends on factors including route of exposure, agent, and species. For example, the median lethal concentration (LC 50 ) for whole-body sarin (Mioduszewski et al., 2002) and cyclosarin (Anthony et al., 2004) exposures is lower in female rats compared to males. In at least one report, female rats are also more sensitive than males to subcutaneous injections of soman (Sket, 1993) . In contrast, no significant sex differences emerge from whole-body exposures of VX (Benton et al., 2006) or subcutaneous injections of tabun (Lundy et al., 1989) . The latter study also reported only a small difference in the subcutaneous median lethal dose (LD 50 ) of soman between the sexes (Lundy et al., 1989) , but the significance of this difference is difficult to determine because statistical analyses were not performed. Species is also a factor; in guinea pigs, the LD 50 of sarin and VX is lower in males compared to females, whereas no sex Toxicology and Applied Pharmacology 287 (2015) 
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Toxicology and Applied Pharmacology j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y t a a p difference is observed following exposure to soman (Fawcett et al., 2009) . Why some studies report sex differences after CWNA intoxication and others do not is unknown. One contributing factor may involve differences in sex-specific gonadal hormones. Males secrete androgens at a relatively constant rate that slowly declines with age (Mooradian et al., 1987) . Females, in contrast, secrete estradiol and progesterone on a cyclical schedule that can significantly change from day to day. For example, the four-day estrous cycle in female rats is defined by two days of diestrus, one day of proestrus, and one day of estrus (Goldman et al., 2007) . Estradiol and progesterone secretions remain relatively quiescent during the first two days of diestrus before peaking in proestrus and then declining by the morning of estrus. Given the widespread distribution of estrogen and progesterone receptors throughout the body, and their effects on physiological functions (Jensen and DeSombre, 1972) , endogenous fluctuations of these hormones could possibly affect females' sensitivity to intoxication with CWNAs from day to day. One commonality among studies using females in CWNA research is that none have controlled for the stage of the estrous cycle (Lundy et al., 1989; Sket, 1993; Mioduszewski et al., 2002; Anthony et al., 2004; Benton et al., 2006; Fawcett et al., 2009) .
The aim of the current study was to determine the toxicity of sarin throughout these hormonal stages in rats by comparing the 24-hour LD 50 of sarin in male, ovariectomized (OVEX) female, and cycling female rats at different stages of the estrous cycle (diestrus, proestrus, and estrus). In addition, baseline plasma acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and carboxylesterase (CE) activity levels were measured. These esterases bind to CWNAs, and numerous studies report sex differences in baseline levels (Leeuwin, 1965; Schmidt and Schmidt, 1978; Illsley and Lamartiniere, 1981; Sterri and Fonnum, 1989; Chanda et al., 1997) , which may affect sensitivity to sarin. If lethality significantly fluctuates throughout the estrous cycle in female rats, consideration should be taken in future studies to reduce variability by controlling for hormonal state.
Material and methods
Subjects. Age-matched adult (200-300 g) male (n = 23), cycling female (n = 76), and ovariectomized female (OVEX; n = 19) Sprague Dawley rats were purchased from Charles River Laboratories (Kingston, NY) and housed under normal 12:12 h light cycle with food and water available ad libitum. OVEX females had their ovaries surgically removed by Charles River Laboratories by an incision through the rear dorsum. To control for the surgical procedures, males and cycling females received a sham procedure, whereby an incision was made on the rear dorsum and immediately stapled. The experimental protocol was approved by the Institutional Animal Care and Use Committee at the USAMRICD, and all procedures were conducted in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89-544), as amended.
Determination of the stage of estrus. The estrous cycle in females was monitored daily by vaginal smears. To perform the smear, a cotton swab moistened in 0.9% saline was briefly inserted into the vaginal opening of female rats. The cotton swab was removed, and the sample applied to a slide. Slides were dipped in a solution of 0.025% methylene blue and examined under a light microscope at 10 ×. The ratio of cornified, epithelial, and/or leukocytic cells was used to determine the stage of estrus as described in Goldman et al. (2007) . Briefly, diestrus was determined by the presence of leukocytes with or without cornified, nucleated epithelial, or non-nucleated epithelial cells; proestrus by the presence of nucleated epithelial cells without leukocytes; and estrus by the presence of cornified cells without leukocytes.
Blood draws and agent exposures. Approximately 4 weeks before exposure to sarin, OVEX female and cycling female rats received vaginal smears for 8 days to determine their estrous cycle. OVEX females were smeared to confirm the lack of cyclicity. To control for the perturbation of the smearing procedure, male rats were removed from their cages and immediately replaced. At the end of the monitoring period, all rats were habituated to the blood collection procedure by gentle restraint in a chux. Four to five days later between 0830 and 0930 h, a subset of rats received blood draws (250 μL per day) from a tail incision. To minimize the number of animals required for blood draws, cycling females (n = 14) received repeated daily blood draws throughout their 4-day estrous cycle (diestrus I, diestrus II, proestrus, and estrus), while OVEX (n = 10) and male rats (n = 10) received a single blood draw. Only cycling females with regular 4-day cycles were included in blood draws. One cycling female was removed from the entire study because evidence of hormonal cyclicity was not observed. OVEX and male rats received "sham" blood draws for the remaining 3 days, where a tail incision was made but no blood collected. All other rats that did not receive blood draws but were included in the LD 50 determination were given tail incisions for 4 days. All animals then recovered for 2 weeks before exposure to sarin.
Five days before exposure to sarin, all females received vaginal smears to confirm hormonal stage. On the day of exposures, cycling females were designated to a group by the stage of their estrous cycle into diestrus, proestrus, or estrus. Given the similar hormonal milieu during the morning on the two days of diestrus (Butcher et al., 1974; Schank and McClintock, 1992) , rats in diestrus I and diestrus II were combined to reduce the overall number of required animals. Between 0930 and 1200 h, all rats were subcutaneously injected with sarin (65.8-239.1 μg/kg; 0.5 mL/kg). Each rat was then continuously monitored by an observer for 2 h and then every 30 min thereafter until 1700 h. Rats surviving the 24-hour time period were euthanized by injection of a pentobarbital-based euthanasia solution followed by perforation of the diaphragm.
Enzyme assays. Cholinesterase assays: Blood AChE and BuChE were measured using a modification of the WRAIR whole blood cholinesterase assay (Gordon et al., 2005) . Briefly, fresh rat whole blood was diluted 1:10 in water and 10 μL were added into 96-well plates. The reactions were initiated by the addition of 290 μL of 50 mM sodium phosphate buffer (pH 8.0) containing one of the following substrates at 1 mM: acetylthiocholine, propionylthiocholine, or butyrylthiocholine. The reactions were conducted at 25°C and monitored at 324 nm in a Molecular Dynamics model SpectraMax Plus plate reader (Sunnyvale, CA) under the control of SoftMax Ver. 5.4 software (Molecular Dynamics, Inc.) by tracking hydrolysis of 4,4′-dithiodiopyridine (DTP), added at 0.2 mM. AChE and BuChE activities (in μmol/min/mL) were calculated for each sample. The product concentration was determined using the molar extinction coefficient Mε 324 = 12,517 cm
. Carboxylesterase (CE) assay: Rat plasma was prepared by centrifugation of whole blood at 3000 × g for 10 min at 4°C, and then flash frozen on dry ice and stored at −80°C. Plasma CE activities were determined as described by Hashinotsume et al. (1978) . Samples (10 μL) were preincubated with 10 μM eserine and 10 mM EDTA for 30 min in reaction buffer containing 50 mM HEPES pH 7.4 in a total volume of 280 μL. Treated samples were loaded into a 96-microtiter plate well, and the reaction was initiated by the addition of 20 μL p-nitrophenyl acetate (2.5 mM final concentration). Samples were analyzed at 25°C by monitoring absorbance at 400 nm using a Molecular Dynamics model SpectraMax Plus plate reader with SoftMax Ver. 5.4 software. The product concentration was determined with the molar extinction coefficient at pH 7.4 for pnitrophenol (Mε 400 = 7860 cm
).
Data analyses. A stagewise, adaptive dose design was used to determine the 24 h LD 50 of sarin (Feder et al., 1991a (Feder et al., , 1991b (Feder et al., , 1991c . In the first stage, agent doses were selected to span the predicted range of lethality from 0% to 100%. Animals were allocated randomly to agent doses per stage (where the first stage used 2 animals each per 5 agent doses). The lethality results from the first stage were used to select agent doses for the second stage. In the subsequent stages, agent doses were selected to further focus on doses with a 50% lethality response and/or to better estimate the dose response curve. After each stage, probit dose response models using maximum likelihood methods were fitted to the combined data for all stages (Finney, 1971; Feder et al., 1991b) . The stage process continued until the half width of the 95% confidence interval (CI) defined as (Upper Bound-Lower Bound)/(2 × LD 50 ) for the 24 h LD 50 was less than 0.4 or a maximum of 32 animals were used. Output from the stagewise adaptive dose program for each group was used to calculate a ratio of the LD 50 values for pairs of groups and the respective 95% CI. This ratio and the respective 95% CI was used to compare LD 50 values between groups. If the 95% CI did not encompass the value of 1.0, then the LD 50 values of the groups were determined to be significantly different. Statistical comparisons of the activity levels of AChE, BuChE, and CE were tested with one-way ANOVAs. Four separate analyses were conducted with male and OVEX females and one group of cycling females from each stage of the estrous cycle (diestrus I, diestrus II, proestrus, and estrus) because cycling females provided data for each stage of the estrous cycle. Since the male and OVEX female groups were used in all four analyses, statistical significance of the main effect of group was determined using a Bonferroni adjusted p-value (p ≤ 0.0125). Significant main effects of esterase activities were followed by a Tukey's multiple comparison test to compare all group pairs with a Bonferroni adjusted p-value (p ≤ 0.0167).
Results

h sarin LD 50
Female rats in proestrus had a significantly higher 24 h sarin LD 50 compared to females in estrus or females with their ovaries removed (Table 1 ; p b 0.05). No differences were observed among any of the female groups compared to the male group. Plasma AChE, BuChE, and CE Baseline activity levels of plasma AChE, BuChE, and CE varied throughout the estrous cycle when compared to male and OVEX rats (Fig. 1 ). Significant main effects of esterase activities after Bonferroni adjustment (p ≤ 0.0125; Table 2) were observed for most of the esterases in all four comparisons (male, OVEX, and one stage of the estrous cycle) except for the levels of AChE in proestrous and CE in diestrous II females when compared to males and OVEX females. Tukey's multiple comparison test revealed that females in diestrus I (p = 0.004), diestrus II (p b 0.001), and estrus (p = 0.001) had significantly lower plasma AChE activity than males. Activities of AChE were not different in OVEX females compared to males or cycling females. Females at each stage of the estrous cycle had significantly more BuChE activity than males (p b 0.001), while levels of BuChE (p = 0.001) were lower in OVEX females compared to females in diestrus II. Activities of CE did ⁎ Indicates a significant difference (p b 0.05). Fig. 1 . Activity levels of (1.1) AChE, (1.2) BuChE, and (1.3) CE in male, OVEX, diestrous I, diestrous II, proestrous, and estrous rats. Significant post-hoc comparisons are shown in letters and symbols. a: AChE in males differed from females in diestrus I, diestrus II, and estrus. b: BuChE in males differed from all females. c: CE in males differed from OVEX females. #: BuChE in OVEX females differed from females in diestrus II. not differ in cycling females compared to males, but OVEX females had lower CE (on average, p = 0.012) than did males.
Discussion
The purpose of this study was to determine if the 24 h sarin LD 50 changes throughout different hormonal states in female rats and in male rats. In addition, we measured the baseline activity levels of AChE, BuChE, and CE during all hormonal states (male, OVEX, diestrus I, diestrus II, proestrus, and estrus) to determine if activity of these esterases fluctuated among the groups. Our results indicated that the sarin LD 50 changed throughout the estrous cycle. Females in proestrus were significantly less sensitive to the lethal effects of sarin compared to OVEX or estrous females, although no overall sex difference was observed. In addition, levels of AChE were generally lower, while BuChE levels were generally higher, in all females compared to males, and OVEX females had lower levels of CE than did males.
Although no sex differences were observed in the LD 50 values, the variability in the cycling females could affect outcomes in CWNArelated toxicity or treatment studies. If one conducted a toxicity study in females, and all subjects were in the same day of the estrous cycle, results from that study could skew future experiments. For example, if all of our female subjects were in estrus during the sarin LD 50 determination, we may have concluded that the female LD 50 of sarin is 110 μg/kg. If, however, all of the female subjects were in proestrus, we may have concluded that the female LD 50 of sarin is~124 μg/kg. Although a relatively small difference, using an LD 50 of sarin of 110 μg/kg in proestrus female rats may be too low to fully or reliably induce toxicity. If one tested potential therapeutics in this scenario, one may incorrectly conclude that the therapeutics possess a higher level of efficacy than actually exists. In light of this possibility, the probability of females cycling together is determined by more than simply chance. Some strains of rats (Schank and McClintock, 1992) but not others (Schank, 2001 ) exhibit partial estrous cycle synchrony by the third cycle (~12 days), which is likely mediated by pheromones. Environmental stimuli, such as initiating vaginal smears or introducing females to a novel environment, also influence synchrony (Shirley, 1978) , suggesting that it is not uncommon for female rats to exhibit similar cycles. As indicated by LD 50 values, protection from sarin in proestrous females compared to OVEX and estrous females may be imparted by the presence of high levels of circulating gonadal hormones, particularly estradiol. Indeed, plasma levels of estradiol peak in the morning of proestrus and decline rapidly by the morning of estrus (Gorski et al., 1975; Schank and McClintock, 1992) . It is difficult to determine if progesterone exhibits a protective effect; progesterone levels rapidly peak and decline during the evening of proestrus and early morning of estrus (Gorski et al., 1975) , and none of the cycling females received sarin during this time period. Incidentally, the LD 50 of sarin in diestrous rats was in between those of proestrus and estrus females, which could have resulted from the gradual increase of estradiol secretion throughout the two days of diestrus. The LD 50 of males resembled that of diestrous rats, which suggests that androgens may also impart some protection against sarin.
The exact mechanism underlying the observed differences in LD 50 values remains to be determined, but it is unclear if the toxic effects of sarin are affected by variation in levels of plasma AChE, BuChE, and/or CE. These esterases varied little throughout the estrous cycle and, as deduced from Sweeney et al. (2006) , endogenous levels of AChE and BuChE in the plasma are likely not high enough to significantly influence the LD 50 of sarin. In addition, the levels of esterase activity do not appear to be associated with LD 50 values. Males had higher AChE levels, and lower BuChE levels, than females, even though no difference between sexes existed in LD 50 values. Furthermore, OVEX females only differed in BuChE activity compared to diestrous II females but the LD 50 of these two hormonal states did not differ, and none of the esterase levels differed between OVEX and proestrous females. Nevertheless, these results do not necessarily preclude endogenous esterases from affecting the observed LD 50 values. Additional studies examining esterase activity throughout the estrous cycle in tissues could address this issue.
Alternatively, the presumably high levels of estradiol in the proestrous rats may have imparted other protective effects that are independent of esterase activity. It is well established that estradiol has potent protective properties against a variety of physiological insults by reducing inflammation, inhibiting apoptotic messengers, and improving mitochondrial function (for review, see Spence and Voskuhl, 2012) . Respiratory failure, a major contributing factor to CWNA-induced lethality (Rickett et al., 1986) , may be delayed or reduced in severity by estradiol. Indeed, estradiol increases bronchodilation by relaxing smooth muscle in the airway (Townsend et al., 2010) possibly by potentiating the effects of norepinephrine on acetylcholine-induced contractions (Townsend et al., 2012) . Testosterone also relaxes the airway (Montano et al., 2014) , which may account for the higher LD 50 of sarin in males compared to OVEX females.
Additional research is required to elucidate the precise underlying mechanisms affecting females' sensitivity to the lethal effects of sarin throughout the estrous cycle. Future studies could examine the potential role of estradiol and progesterone, as well as other hormones that fluctuate with the estrous cycle, such as follicle stimulating hormone and luteinizing hormone. Gonadal hormones are also known to affect seizures (Scharfman and MacLusky, 2006) , and the stage of the estrous cycle may affect how the epileptogenic properties of CWNAs manifest in females. Finally, the efficacy of currently fielded (atropine, 2-PAM, and diazepam) and potentially novel therapeutics could be examined to determine if their therapeutic properties fluctuate throughout the cycle. Nevertheless, the current study supports the hypothesis that the lethality of sarin in female rats is affected by the stage of the estrous cycle. If including female subjects in CWNA research, these results suggest that controlling for the stage of the estrous cycle can reduce potential variability most likely due to cycling gonadal hormones.
Conclusion
The 24 h LD 50 of sarin changes throughout the estrous cycle in female rats. Females in proestrus exhibit a significantly higher LD 50 compared to females in estrus or those females with their ovaries removed. Furthermore, this finding does not appear to be dependent on differences in plasma activity levels of acetylcholinesterase, butyrylcholinesterase, or carboxylesterase. The mechanism underlying the higher LD 50 in proestrus females is unclear but may be related to the presence of estradiol during that stage of the cycle. Although future research is required to elucidate these mechanisms, results from this study underscore the importance of monitoring the estrous cycle when using female rats in CWNA-related research.
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